Lilly, With Tirzepatide Supply Issues Addressed, Raises Guidance By $3bn

Obesity, Diabetes Blockbusters Lead 36% Revenue Growth

 
• By Joseph Haas
Lilly corporate center
Lilly posted 36% year-over-year growth during Q2 2024 • Source: Shutterstock

More from Earnings

More from Business